Form 4: Apellis Pharmaceuticals Executive Sells Shares to Cover Tax Obligations

Mark Jeffrey DeLong, Chief Business & Strategy Officer of Apellis Pharmaceuticals, sold 1,396 shares of common stock on January 22, 2025, to cover tax withholding related to released Restricted Stock Units.

Summary

• On January 22, 2025, Mark Jeffrey DeLong, the Chief Business & Strategy Officer of Apellis Pharmaceuticals, sold 1,396 shares of the company's common stock.
• The sale was executed at a price of $30.4255 per share.
• This transaction was conducted to cover tax withholding obligations arising from the release of Restricted Stock Units on January 21, 2025.
• Following the transaction, DeLong directly owns 84,673 shares of Apellis Pharmaceuticals.

Sentiment

Score: 5

Explanation: The document describes a routine transaction (selling shares to cover taxes), so the sentiment is neutral.

Industry Context

Executive stock sales are a common occurrence, often related to compensation and tax obligations. The market typically analyzes these sales in the context of the executive's overall holdings and the company's performance.

Stakeholder Impact

• The sale of shares by an executive could have a minor impact on shareholder sentiment, but is unlikely to be significant given the context.

Key Dates

Keywords

Apellis Pharmaceuticals, Mark DeLong, stock sale, Form 4, insider trading, Restricted Stock Units, tax withholding, APLS